Overview


According to FutureWise analysis, the market for Insulin Sensitizers is expected to grow with a CAGR of 5.72% over the forecast period 2023-2031, and reach a market value of US$ 23.5 Billion by 2031. 

Insulin sensitizers are drugs employed in the treatment of type 2 diabetes mellitus; a persistent metabolic condition characterized by heightened levels of blood sugar. These medications augment the body's receptiveness to insulin, a pivotal hormone in regulating blood glucose levels. In type 2 diabetes, cells exhibit reduced responsiveness to insulin, resulting in a state known as insulin resistance. Insulin sensitizers serve to surmount this resistance, enabling cells to take in and utilize glucose from the circulatory system more effectively.

One of the most common insulin sensitizer drugs is thiazolidinediones (TZDs), which include medications like pioglitazone and rosiglitazone. TZDs bind to specific receptors in the cells, particularly in adipose tissue, skeletal muscle, and the liver. This action helps to improve glucose uptake and decrease the liver's glucose production, effectively lowering blood sugar levels. Additionally, insulin sensitizers can also have beneficial effects on lipid metabolism. They may increase high-density lipoprotein (HDL) cholesterol levels and decrease triglycerides. This dual action on glucose and lipid metabolism makes insulin sensitizers a valuable treatment option for individuals with type 2 diabetes who often have associated lipid abnormalities.

FutureWise Market Research has published a report that provides an insightful analysis of Insulin Sensitizers Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Insulin Sensitizers Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • Merck & Co.
  • Bristol Myers Squibb
  • AstraZeneca
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Takeda Pharmaceutical

(Note: The list of the major players will be updated with the latest market scenario and trends)

The increasing incidence of type 2 diabetes, a condition for which insulin sensitizers are commonly prescribed, drives the demand for these medications. Heightened awareness about managing diabetes effectively, including insulin sensitizers, contributes to market growth. Advancement in research and development efforts led to introduction of more practical and convenient formulations of insulin sensitizers, potentially expanding their market.  Insulin sensitizers are often combined with other antidiabetic medications, creating a synergistic effect that optimizes blood sugar control and creates enormous market opportunities. Insulin sensitizers, particularly certain classes like thiazolidinediones, are available orally, which patients’ over-injectable insulin often prefer, boosting the market growth.

However, Insulin sensitizers, like any medication, may be associated with potential side effects, including weight gain, fluid retention, and a potential risk of bone fractures, thus hampering the market growth and limiting their use in some patients. Stringent regulatory approval processes and compliance standards for new medications can slow the introduction of innovative insulin sensitizers. Developing new classes of antidiabetic medications, including incretin-based therapies and SGLT-2 inhibitors, may compete with insulin sensitizers, restraining the market growth.

By Type of Insulin Sensitizers

  • Thiazolidinediones (TZDs)
  • Biguanides
  • Incretin-based therapies
  • Others

By Indication

  • Type 2 Diabetes
  • Prediabetes
  • Polycystic Ovary Syndrome (PCOS)

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due he high prevalence of type 2 diabetes in the region, robust healthcare infrastructure, the prominent presence of key industry players, and heightened research endeavors in this geographical region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Insulin Sensitizers Market By Type of Insulin Sensitizers, By Indication, By Route of Administration, By Distribution Channel, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Insulin Sensitizers Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Insulin Sensitizers Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Insulin Sensitizers Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Insulin Sensitizers Market, By Type of Insulin Sensitizers Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Thiazolidinediones (TZDs)
      2. Biguanides
      3. Incretin-based therapies
      4. Others
  • 8.  Insulin Sensitizers Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Type 2 Diabetes
      2. Prediabetes
      3. Polycystic Ovary Syndrome (PCOS)
  • 9.  Insulin Sensitizers Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Oral
      2. Injectable
  • 10.  Insulin Sensitizers Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
  • 11.  North America Insulin Sensitizers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.  Latin America Insulin Sensitizers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.  Europe Insulin Sensitizers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.  Asia Pacific Insulin Sensitizers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031  

  • 15.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 17.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Eli Lilly and Company
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Novo Nordisk
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Sanofi
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Merck & Co.
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Bristol Myers Squibb
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. AstraZeneca
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Boehringer Ingelheim
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Johnson & Johnson
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Takeda Pharmaceutical
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview

  • 18.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients